These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 23586056)
1. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer. Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056 [TBL] [Abstract][Full Text] [Related]
2. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer. Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257 [TBL] [Abstract][Full Text] [Related]
3. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2. Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477 [TBL] [Abstract][Full Text] [Related]
4. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936 [TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib. Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023 [TBL] [Abstract][Full Text] [Related]
6. Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis. Xiang M; Jiang HG; Shu Y; Chen YJ; Jin J; Zhu YM; Li MY; Wu JN; Li J Int J Biol Sci; 2020; 16(9):1536-1550. PubMed ID: 32226300 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified]. Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942 [TBL] [Abstract][Full Text] [Related]
8. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. Pal HC; Sharma S; Strickland LR; Agarwal J; Athar M; Elmets CA; Afaq F PLoS One; 2013; 8(10):e77270. PubMed ID: 24124611 [TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650]. Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714 [TBL] [Abstract][Full Text] [Related]
10. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer. Yang G; Yao Y; Zhou J; Zhao Q Oncol Rep; 2012 Jun; 27(6):2066-72. PubMed ID: 22446631 [TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. Tang N; Zhang Q; Fang S; Han X; Wang Z Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073 [TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients. Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694 [TBL] [Abstract][Full Text] [Related]
13. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy. Feng S; Wang Y; Cai K; Wu H; Xiong G; Wang H; Zhang Z PLoS One; 2015; 10(10):e0140794. PubMed ID: 26474174 [TBL] [Abstract][Full Text] [Related]
14. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer]. Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053 [TBL] [Abstract][Full Text] [Related]
15. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines. Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts. Cui J; Zhang Y; Su D; Li T; Li Y Thorac Cancer; 2018 Sep; 9(9):1156-1165. PubMed ID: 30047610 [TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis. Chen P; Dai CH; Shi ZH; Wang Y; Wu JN; Chen K; Su JY; Li J Apoptosis; 2021 Dec; 26(11-12):639-656. PubMed ID: 34743246 [TBL] [Abstract][Full Text] [Related]
18. [Clinical Analysis of Icotinib on Beneficiary of Advanced Non-small Cell Lung Cancer with EGFR Common Mutation]. Jiang X; Wang W; Zhang Y Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):200-6. PubMed ID: 27118647 [TBL] [Abstract][Full Text] [Related]
19. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
20. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified]. Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]